Judge refuses to throw out $9 billion judgment against Actos makers
A Louisiana federal judge refused to throw out a $9 billion judgment against Takeda Pharmaceuticals and Eli Lilly & Co., alleging the companies hid bladder cancer risks with its blockbuster type 2 diabetes drug Actos.
Experimental testosterone therapy outperforms leading testosterone gel in studies
The experimental testosterone treatment Androxal performed better than a leading testosterone gel and placebo in the first of two studies, Repros Therapeutics Inc. announced.
Teens whose mothers had gestational diabetes are at greater risk of type 2 diabetes
Obese teenagers whose mothers had gestational diabetes while pregnant with them are at greater risk of developing Type 2 diabetes, a new study shows.
Fifteen injuries linked to defective jaw implant; device has been recalled
Certain implants used in adults, children and infants to lengthen and stabilize the lower jawbone or side jaw to correct birth defects or post-traumatic defects are being recalled because the device may reverse direction. To date, this device defect has
Drug companies race for FDA approval on new class of cholesterol lowering drugs
Pharmaceutical companies are in a desperate race to get their new type of cholesterol-lowering treatment reviewed and approved by drug regulators so they can be the first to hit the market and take a bite out of the multibillion-dollar statin
New testosterone treatment in development carries fewer side effects
Testosterone levels in men typically drop as a man ages, but when it drops too low it signals a possible problem. In many cases the drop can be associated with obesity, diabetes and circulatory disease.
Combining old diabetes drug with new improves blood sugar control
Combining the commonly used metformin with another class of medication can greatly improve blood sugar control in Type 2 diabetics, according to new research.
Young, African-American dialysis patients at greater risk of dying
Young African-Americans on dialysis are 1.5 times more likely to die than white dialysis patients, according to a study published in the Journal of the American Society of Nephrology.